» Articles » PMID: 29514782

The MYC Oncogene is a Global Regulator of the Immune Response

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2018 Mar 9
PMID 29514782
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

The MYC proto-oncogene is a gene product that coordinates the transcriptional regulation of a multitude of genes that are essential to cellular programs required for normal as well as neoplastic cellular growth and proliferation, including cell cycle, self-renewal, survival, cell growth, metabolism, protein and ribosomal biogenesis, and differentiation. Here, we propose that MYC regulates these programs in a manner that is coordinated with a global influence on the host immune response. MYC had been presumed to contribute to tumorigenesis through tumor cell-intrinsic influences. More recently, MYC expression in tumor cells has been shown to regulate the tumor microenvironment through effects on both innate and adaptive immune effector cells and immune regulatory cytokines. Then, MYC was shown to regulate the expression of the immune checkpoint gene products CD47 and programmed death-ligand 1. Similarly, other oncogenes, which are known to modulate MYC, have been shown to regulate immune checkpoints. Hence, MYC may generally prevent highly proliferative cells from eliciting an immune response. MYC-driven neoplastic cells have coopted this mechanism to bypass immune detection. Thus, MYC inactivation can restore the immune response against a tumor. MYC-induced tumors may be particularly sensitive to immuno-oncology therapeutic interventions.

Citing Articles

MYC in cancer: from undruggable target to clinical trials.

Whitfield J, Soucek L Nat Rev Drug Discov. 2025; .

PMID: 39972241 DOI: 10.1038/s41573-025-01143-2.


Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications.

Priya , Kumar A, Kumar D 3 Biotech. 2025; 15(1):33.

PMID: 39777154 PMC: 11700964. DOI: 10.1007/s13205-024-04195-0.


Identification of Transcriptional Regulators of Immune Evasion Across Cancers: An Alternative Immunotherapeutic Strategy for Cholangiocarcinoma.

Venkatraman S, Balasubramanian B, Kongpracha P, Yangngam S, Chuangchot N, Khanaruksombat S Cancers (Basel). 2025; 16(24.

PMID: 39766097 PMC: 11674672. DOI: 10.3390/cancers16244197.


Antibody/siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem-Like Behavior in Triple-Negative Breast Cancer Cells.

Hoover E, Day E J Biomed Mater Res A. 2025; 113(1):e37867.

PMID: 39760151 PMC: 11800355. DOI: 10.1002/jbm.a.37867.


Advances in biomarkers for immunotherapy in small-cell lung cancer.

Li H, Zhao P, Tian L, Lu Y, Wang X, Shao W Front Immunol. 2024; 15:1490590.

PMID: 39723215 PMC: 11668642. DOI: 10.3389/fimmu.2024.1490590.


References
1.
Lenardo M, Rustgi A, Schievella A, Bernards R . Suppression of MHC class I gene expression by N-myc through enhancer inactivation. EMBO J. 1989; 8(11):3351-5. PMC: 401475. DOI: 10.1002/j.1460-2075.1989.tb08497.x. View

2.
Felsher D . Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphat Res Biol. 2008; 6(3-4):149-54. DOI: 10.1089/lrb.2008.63403. View

3.
Zheng H, Ying H, Yan H, Kimmelman A, Hiller D, Chen A . Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol. 2009; 73:427-37. DOI: 10.1101/sqb.2008.73.047. View

4.
Depinho R, Mitsock L, Hatton K, Ferrier P, Zimmerman K, Legouy E . Myc family of cellular oncogenes. J Cell Biochem. 1987; 33(4):257-66. DOI: 10.1002/jcb.240330404. View

5.
Pai-Scherf L, Blumenthal G, Li H, Subramaniam S, Mishra-Kalyani P, He K . FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017; 22(11):1392-1399. PMC: 5679831. DOI: 10.1634/theoncologist.2017-0078. View